AVAX Technologies Inc (AVXT)

[katter]

The stock of AVAX TECHS INCORPORATED (OTCMKTS:AVXT) registered a decrease of 52% in short interest. AVXT’s total short interest was 2,400 shares in February as published by FINRA. Its down 52% from 5,000 shares, reported previously. The stock increased 24.09% or $0.0033 on February 26, hitting $0.017. About 44,200 shares traded hands. AVAX Technologies Inc (OTCMKTS:AVXT) has risen 240.00% since July 31, 2015 and is uptrending. It has outperformed by 247.33% the S&P500.

AVAX Technologies, Inc. is a development stage biotechnology firm specializing in the development and commercialization of vaccine therapies and other technologies for the treatment of cancer. The company has a market cap of $1.39 million. The Company’s vaccine consists of autologous (the patient’s own) cancer cells that have been treated with a chemical (haptenized) to make them more visible to the patient’s immune system. It currently has negative earnings. AVAX refer to its cancer vaccine technology as autologous cell (AC) vaccine platform.